Compare · CV vs OM
CV vs OM
Side-by-side comparison of CapsoVision Inc. (CV) and Outset Medical Inc. (OM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CV and OM operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- OM carries a market cap of $1.64B.
- OM has been more active in the news (6 items in the past 4 weeks vs 2 for CV).
- OM has more recent analyst coverage (13 ratings vs 2 for CV).
- Company
- CapsoVision Inc.
- Outset Medical Inc.
- Price
- $6.05+5.03%
- $4.53-0.88%
- Market cap
- -
- $1.64B
- 1M return
- -27.49%
- -
- 1Y return
- +51.00%
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2020
- News (4w)
- 2
- 6
- Recent ratings
- 2
- 13
OM
Outset Medical Inc.
Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It offers Tablo Hemodialysis System, which comprises of a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
Latest CV
- SEC Form EFFECT filed by CapsoVision Inc.
- SEC Form S-1 filed by CapsoVision Inc.
- SEC Form 3 filed by new insider Shen Ching Hang
- SEC Form 3 filed by new insider Harari Eliyahou Et Al
- SEC Form 10-K filed by CapsoVision Inc.
- CapsoVision Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- CapsoVision Reports Fourth Quarter and Full Year 2025 Financial Results
- SEC Form 4 filed by Tsai Chen Lung
- SEC Form 4 filed by Kuo Hui Ying
- SEC Form 4 filed by King Wen-Herng Henry
Latest OM
- SEC Form DEFA14A filed by Outset Medical Inc.
- SEC Form DEF 14A filed by Outset Medical Inc.
- SEC Form 4 filed by Elliott Derick A.
- SEC Form 3 filed by new insider Elliott Derick A.
- Outset Medical Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Outset Medical Names Derick Elliott as Executive Vice President of Commercial
- Amendment: SEC Form SCHEDULE 13G/A filed by Outset Medical Inc.
- Amendment: New insider Leonard Braden Michael claimed ownership of 1,902,201 shares (SEC Form 3)
- General Counsel Brottem John L. sold $9,521 worth of shares (2,842 units at $3.35), decreasing direct ownership by 8% to 32,935 units (SEC Form 4)
- Chair and CEO Trigg Leslie sold $11,259 worth of shares (3,361 units at $3.35), decreasing direct ownership by 3% to 102,342 units (SEC Form 4)